Rhinovirus Infections R&D Pipeline Analysis Report, H2-2018 - Comprehensive Pipeline Review on Ongoing Clinical and Pre-Clinical Studies - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Rhinovirus Infections R&D Pipeline Analysis Report, H2-2018” report has been added to ResearchAndMarkets.com’s offering.

The Rhinovirus Infections pipeline guide presents complete overview of drugs currently being developed for Rhinovirus Infections. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Rhinovirus Infections pipeline candidate.

Research and Development progress along with latest news related to each of the Rhinovirus Infections pipeline candidates is included.

Major companies participating in therapeutic development of Rhinovirus Infections are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.

Amid strong interest for cure of Rhinovirus Infections from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Rhinovirus Infections clinical and pre clinical products.

The report assists in identifying potential upcoming companies and drugs in Rhinovirus Infections pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Key Topics Covered:

I. Key Findings

1. Companies Investing in Rhinovirus Infections Pipeline include

2. Pipeline Candidates

II. Insights into Rhinovirus Infections Pipeline

1. Disease Overview2. Phase wise Pipeline Compounds3. Company wise Rhinovirus Infections Pipeline Compounds

4. Rhinovirus Infections Pipeline by Mechanism of Action

III. Rhinovirus Infections Pipeline Compound Details

1. Snapshot

2. Drug Overview

3. Mechanism of Action4. Current Status5. Clinical Trial Details

IV. Rhinovirus Infections Pipeline Company Briefs

V. Latest News and Developments in Global Rhinovirus Infections Pipeline Market

VI. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/jp9qpz/rhinovirus?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005642/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 08:25 AM/DISC: 09/25/2018 08:25 AM


Update hourly